For both induction and maintenance therapy, subcutaneous guselkumab significantly improves clinical outcomes in patients with ...

A Phase 2b/3, randomised, double-blind, placebo-controlled, parallel-group, multicentre protocol to evaluate the efficacy and safety of guselkumab in participants with moderately to severely active ...

Johnson & Johnson (J&J) has shared positive results from a late-stage study evaluating a subcutaneous (SC) version of Tremfya ...

The CoTikiS trial’s ten-week results from the 50-week trial saw as an endoscopic improvement rate of 32% in patients.

Reducing glucocorticoid use in the treatment of giant cell arteritis and polymyalgia rheumatica — due to the steroid’s host ...

and Tremfya (guselkumab), and Sun Pharma's Ilumya (tildrakizumab). In Crohn's, Skyrizi, Stelara, and Ilumya are already approved by the FDA, while Tremfya is under review, having been submitted to ...

Skyrizi (risankizumab) is the first IL-23-selective drug to be cleared for the inflammatory bowel disease – ahead of rivals like Johnson & Johnson's Tremfya (guselkumab), and Sun Pharma's Ilumya ...

Paul Goepfert, MD, Director for the Alabama Vaccine Research Clinic, stated: "I'm excited for the opportunity to follow-up on ...

A 175% increase in human papilloma virus vaccination initiation was observed following the implementation of an office based, same-day vaccine program in a dermatology clinic. Vaccination rates for ...